Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;10(2):249–259. doi: 10.1111/j.1750-3639.2000.tb00258.x

Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas

Tammy Sung 1, Douglas C Miller 2,4, Roberta L Hayes 3, Michelle Alonso 1, Herman Yee 1,4, Elizabeth W Newcomb 1,4,✉
PMCID: PMC8098142  PMID: 10764044

Abstract

Classification of high grade astrocytomas of children into genetic subtypes similar to the adult remains to be defined. Here we report an extensive characterization of 29 high grade pediatric astrocytomas, 7 WHO grade III and 22 WHO grade IV, for genetic alterations frequently observed in high grade adult astrocytomas occurring in either the p53/MDM2/p14ARF or Rb/CDK4/p16INK4a tumor suppressor pathways. In addition, we have assessed the contribution of EGFR overexpression and amplification and LOH for chromosome 10, two genetic alterations commonly associated with the development of de novo adult glioblastoma for their roles in the development of de novo astrocytomas of childhood. Our results suggest two major differences in the genetic pathway(s) leading to the formation of de novo high grade astrocytomas in children compared with those of the adult. Our findings show preferential inactivation of the p53 tumor suppressor pathway in > 95% of pediatric astrocytomas versus inactivation of the Rb tumor suppressor pathway in < 25% of the same tumors. In addition, de novo high grade pediatric astrocytomas lack amplification of the EGFR gene compared with EGFR amplification in one‐third of adult glioblastomas. Since drug treatments and gene therapy strategies exploit specific genetic alterations in tumor cells, our findings have important implications for the future development of treatments for high grade pediatric astrocytomas.

Full Text

The Full Text of this article is available as a PDF (129.0 KB).

References

  • 1. Baswlga J , Norton L , Albanell J , Kim YM , Mendelsohn J ( 1998. ) Recombinant humanized anti‐HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts . Cancer Res 58 : 2825 – 2831 . [PubMed] [Google Scholar]
  • 2. Biernat W , Kleihues P , Yonekawa Y , Ohgaki H ( 1997. ) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas . J Neuropathol Exp Neurol 56 : 180 – 185 . [DOI] [PubMed] [Google Scholar]
  • 3. Biernat W , Tohma Y , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas . Acta Neuropathol 94 : 303 – 309 . [DOI] [PubMed] [Google Scholar]
  • 4. Bostrom J , Cobbers JMJL , Wolter M , Tabatabai G , Weber RG , Lichter P , Collins VP , Reifenberger G ( 1998. ) Mutation of the PTEN(MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q . Cancer Res 58 : 29 – 33 . [PubMed] [Google Scholar]
  • 5. Burns KL , Ueki K , Jhung SL , Koh J , Louis DN ( 1998. ) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas . J Neuropathol Exp Neurol 57 : 122 – 130 . [DOI] [PubMed] [Google Scholar]
  • 6. Cheng Y , Ng H‐K , Ding M , Zhang S‐F , Pang J C‐S , Lo K‐W ( 1999. ) Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors . J Neuropathol Exp Neurol 58 : 120 – 128 . [DOI] [PubMed] [Google Scholar]
  • 7. Cheng Y , Ng H‐K , Zhang S‐F , Ding M , Pang JC‐S , Zheng J , Poon WS ( 1999. ) Genetic alterations in pediatric high‐grade astrocytomas . Human Pathol 30 : 1284 – 1290 . [DOI] [PubMed] [Google Scholar]
  • 8. Dohrmann GJ , Farwell JR , Flannery JT ( 1975. ) Glioblastoma in children . J Neurosurg 44 : 442 – 448 . [DOI] [PubMed] [Google Scholar]
  • 9. Duerr E‐M , Rollbrocker B , Hayashi Y , Peters N , Meyer‐Puttlitz B , Louis DN , Schramm J , Wiestler OD , Persons R , Eng C , von Deimling A ( 1998. ) PTEN mutations in gliomas and glioneuronal tumors . Oncogene 16 : 2259 – 2264 . [DOI] [PubMed] [Google Scholar]
  • 10. Felix CA , Slavc I , Dunn M , Strauss EA , Phillips PC , Rorke LB , Sutton L , Bunin GR , Biegel JA ( 1995. ) p53 gene mutations in pediatric brain tumors . Med Ped Oncol 25 : 431 – 436 . [DOI] [PubMed] [Google Scholar]
  • 11. Frankel RH , Bayona W , Koslow M , Newcomb EW ( 1992. ) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency . Cancer Res 52 : 1427 – 1433 . [PubMed] [Google Scholar]
  • 12. Freedman D , Levine AJ ( 1999. ) Regulation of the p53 protein by the MDM2 oncoprotein‐Thirty‐eighth G.H.A. Clowes memorial award lecture . Cancer Res 59 : 1 – 7 . [PubMed] [Google Scholar]
  • 13. Fults D , Brockmeyer D , Tullous MW , Pedone CA , Cawthon RM ( 1992. ) p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression . Cancer Res 52 : 674 – 679 . [PubMed] [Google Scholar]
  • 14. Gorgoulis VG , Zacharatos P , Kotsinas A , Liloglou T , Kyroudi A , Veslemes M , Rassidakis A , Halazonetis , Field JK , Kittas C ( 1998. ) Alterations of the p16‐Rb pathway and the chromosome locus 9p21‐22 in non‐small‐cell lung carcinomas: Relationship with p53 and MDM2 protein expression . Am J Pathol 153 : 1749 – 1765 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Hayashi Y , Ueki K , Waha A , Wiestler OD , Louis DN , von Deimling A ( 1997. ) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme . Brain Pathol 7 : 871 – 875 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. He J , Allen JR , Collins VP , Allalunis‐Turner MJ , Godbout R , Day RS , James CD ( 1994. ) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines . Cancer Res 54 : 5804 – 5807 . [PubMed] [Google Scholar]
  • 17. He J , Reifenberger G , Liu L , Collins VP , James CD ( 1994. ) Analysis of glioma cell lines for amplification and overexpression of MDM2 . Genes Chromosome Cancer 11 : 91 – 96 . [DOI] [PubMed] [Google Scholar]
  • 18. Jones SN , Roe AE , Donehower LA , Bradley A ( 1995. ) Rescue of embryonic lethality in Mdm2‐deficient mice by absence of p53 . Nature 378 : 206 – 208 . [DOI] [PubMed] [Google Scholar]
  • 19. Kleihues P , Burger PC , Plate KH , Ohgaki H , Cavenee WK ( 1997. ) Glioblastoma In : Pathology and Genetics of Tumours of the Nervous System . Kleihues P , Cavenee WK ( eds. ), IARC Press; , Lyon , pp 16 – 24 . [Google Scholar]
  • 20. Kleihues P , Burger PC , Scheithauer BW ( 1993. ) Histological Typing of Tumors of the Central Nervous System . Springer‐Verlag; Berlin , Heidelberg , New York . [Google Scholar]
  • 21. Korkolopoulou P , Christodoulou P , Kouzelis K , Hadjiyannakis M , Priftis A , Stamoulis G , Seretis A , Thomas‐Tsagli E ( 1997. ) MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor . Br J Cancer 75 : 1269 – 1278 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Lang FF , Miller DC , Koslow M , Newcomb EW ( 1994. ) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors . J Neurosurg 81 : 427 – 436 . [DOI] [PubMed] [Google Scholar]
  • 23. Lang FF , Miller DC , Pisharody S , Koslow M , Newcomb , EW ( 1994. ) High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas . Oncogene 9 : 949 – 954 . [PubMed] [Google Scholar]
  • 24. Litofsky NS , Hinton D , Raffel C ( 1994. ) The lack of a role for p53 in astocytomas in pediatric patients . Neurosurgery 34 : 967 – 973 . [DOI] [PubMed] [Google Scholar]
  • 25. Louis DN , Rubio M‐P , Correa KM , Gusella JF , von Deimling A ( 1993. ) Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens . J Neuropathol Exp Neurol 52 : 507 – 515 . [DOI] [PubMed] [Google Scholar]
  • 26. McLendon RE , Enterline DS , Tien RD , Thorstad WL , Bruner JM. ( 1998. ) Tumors of central neuroepithelial origin In : Russell and Rubinstein's Pathology of Tumors of the Nervous System , 6th Ed. Bigner DD , McLendon RE , Bruner JM , ( eds ), pp. 337 – 338 , Arnold; : London . [Google Scholar]
  • 27. Moscatello DK , Ramirez G , Wong AJ ( 1997. ) A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors . Cancer Res 57 : 1419 – 1424 . [PubMed] [Google Scholar]
  • 28. Newcomb EW , Cohen C , Lee SR , Bhalla SK , Bloom J , Hayes RL , Miller DC ( 1998. ) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl‐2 genes . Brain Pathol 8 : 655 – 667 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Newcomb EW , Madonia WJ , Pisharody S , Lang FF , Koslow M , Miller DC ( 1993. ) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme . Brain Pathol 3 : 229 – 235 . [DOI] [PubMed] [Google Scholar]
  • 30. Orellana C , Hernandez‐Marti M , Marinez F , Castel V , Millan JM , Alvarez‐Garijo JA , Prieto F , Badia L ( 1998. ) Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations . Cancer Genet Cytogenet 102 : 93 – 99 . [DOI] [PubMed] [Google Scholar]
  • 31. Pegram M , Hsu S , Lewis G , Pietras R , Beryt M , Sliwkowski M , Coombs D , Baly D , Kabbinavar F , Slamon D ( 1999. ) Inhibitory effects of combinations of HER‐1/neu antibody and chemotherapeutic agents used for treatment of human breast cancers . Oncogene 18 : 2241 – 2251 . [DOI] [PubMed] [Google Scholar]
  • 32. Pollack IF , Hamilton RL , Finkelstein SD , Campbell JW , Martinez AJ , Sherwin RN , Bozik ME , Gollin SM ( 1997. ) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood . Cancer Res 57 : 304 – 309 . [PubMed] [Google Scholar]
  • 33. Pomerantz J , Schreiber‐Agus N , Liegeois NJ , Silverman A , Alland L , Chin L , Potes J , Chen K , Orlow I , Lee H‐W , Cordon‐Cardo C , DePinho RA ( 1998. ) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53 . Cell 92 : 713 – 723 . [DOI] [PubMed] [Google Scholar]
  • 34. Quelle DE , Zindy F , Ashmun RA , Sherr CJ ( 1995. ) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest . Cell 83 : 993 – 1000 . [DOI] [PubMed] [Google Scholar]
  • 35. Rainov NG , Dobberstein K‐U , Bahn H , Holzhausen H‐J , Lauten‐Schlager C , Heidecke V , Burkert W ( 1997. ) Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor‐suppressor gene products on survival . J Neuro-Oncol 35 : 13 – 28 . [DOI] [PubMed] [Google Scholar]
  • 36. Rao LS , Miller DC , Newcomb EW ( 1997. ) A correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4 genes in astrocytomas . Diag Mol Pathol 6 : 15 – 122 . [DOI] [PubMed] [Google Scholar]
  • 37. Rasheed BK , McLendon RE , Herndon JE , Friedman HS , Friedman AH , Bigner DD , Bigner SH ( 1994. ) Alterations of the TP53 gene in human gliomas . Cancer Res 54 : 1324 – 1330 . [PubMed] [Google Scholar]
  • 38. Reifenberger G , Liu L , Ichimura K , Schmidt EE , Collins VP ( 1993. ) Amplification and overexpression of MDM2 gene in a subset of human malignant gliomas without p53 mutations . Cancer Res 53 : 2736 – 2739 . [PubMed] [Google Scholar]
  • 39. Schlott T , Reimer S , Jahns A , Ohlenbusch A , Ruschenburg I , Nagel H , Droese M ( 1997. ) Point mutation and nucleotide insertions in the MDM2 zinc finger structure of human tumours . J Pathol 182 : 54 – 61 . [DOI] [PubMed] [Google Scholar]
  • 40. Soong R , Iacopetta BJ ( 1997. ) A rapid and nonisotopic method for screening and sequencing of p53 gene mutations in formalin‐fixed, paraffin‐embedded tumors . Mod Pathol 10 : 252 – 258 . [PubMed] [Google Scholar]
  • 41. Steck PA , Pershouse MA , Jasser SA , Yung WKA , Lin H , Ligon AH , Langford LA , Baumgard ML , Hattier T , Davis T , Frye C , Hu R , Swedlund B , Teng DHF , Tavtigian SV ( 1997. ) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers . Nature Genetics 15 : 356 – 362 . [DOI] [PubMed] [Google Scholar]
  • 42. Sure U , Ruedi D , Tachibana O , Yonekawa Y , Ohgaki H , Kleihues P , Hegi ME ( 1997. ) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas . J Neuropathol Exp Neurol 56 : 782 – 789 . [PubMed] [Google Scholar]
  • 43. Teng D H‐F , Hu R , Lin H , Davis T , Iliev D , Frye C , Swedlund B , Hansen KL , Vinson VL , Gumpper KL , Ellis L , El‐Naggar A , Frazier M , Jasser S , Langford LA , Lee J , Mills GB , Pershouse MA , Pollack RE , Tornos C , Troncoso P , Yung WKA , Fujii G , Berson Am Bookstein R , Bolen JB , Tavtigian SV , Steck PA ( 1997. ) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines . Cancer Res 57 : 5221 – 5225 . [PubMed] [Google Scholar]
  • 44. Tohma Y , Gratas C , Biernat W , Peraud A , Fukuda M , Yonekawa Y , Kleihues P , Ohgaki H ( 1998. ) PTEN(MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas . J Neuropathol Exp Neurol 57 : 684 – 689 . [DOI] [PubMed] [Google Scholar]
  • 45. Ueki K , Ono Y , Henson JW , Efird JT , von Deimling A , Louis DN ( 1996. ) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated . Cancer Res 56 : 150 – 153 . [PubMed] [Google Scholar]
  • 46. von Deimling A , Louis DN , von Ammon K , Petersen I , Hoell T , Chung RY , Martuza RL , Schoenfeld DA , Yasargil MG , Wiestler OD , Seizinger BR ( 1992. ) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme . J Neurosurg 77 : 295 – 301 . [DOI] [PubMed] [Google Scholar]
  • 47. von Deimling A , von Ammon K , Schoenfeld D , Wiestler OD , Seizinger BR , Louis DN ( 1993. ) Subsets of glioblastoma multiforme defined by molecular genetic analysis . Brain Pathol 3 : 19 – 26 . [DOI] [PubMed] [Google Scholar]
  • 48. Wang SI , Puc J , Li J , Bruce JN , Cairns P Sidransky D , Parsons R ( 1997. ) Somatic mutations of PTEN in glioblastoma multiforme . Cancer Res 57 : 4183 – 4186 . [PubMed] [Google Scholar]
  • 49. Watanabe K , Tachibana O , Sato K , Yonekawa Y , Kleihues P , Ohgaki H ( 1997. ) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas . Brain Pathol 6 : 217 – 224 . [DOI] [PubMed] [Google Scholar]
  • 50. Wu X , Bayle H , Olson D , Levine AJ ( 1993. ) The p53‐mdm‐2 autoregulatory feedback loop . Genes & Develop 7 : 1126 – 1132 . [DOI] [PubMed] [Google Scholar]
  • 51. Yang X‐D , Jia X‐C , Corvalan RF , Wang P , Davis CG , Jakobovits A ( 1999. ) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy . Cancer Res 59 : 1236 – 1243 . [PubMed] [Google Scholar]
  • 52. Zhang Y , Xiong Y , Yarbrough WG ( 1998. ) ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways . Cell 92 : 725 – 734 . [DOI] [PubMed] [Google Scholar]
  • 53. Zhang S , Feng X , Koga H , Ichikawa T , Abe S , Kumanishi T ( 1993. ) p53 gene mutations in pontine gliomas of juvenile onset . Biochem Biophys Res Commun 196 : 851 – 857 . [DOI] [PubMed] [Google Scholar]
  • 54. Zar , JH ( 1984. ) Biostatistical Analysis . Prentice‐Hall, Inc. , Englewood Cliffs , NJ . [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES